Literature DB >> 17093970

Molecular impact of clenbuterol and isometric strength training on rat EDL muscles.

Rémi Mounier1, Hélian Cavalié, Gérard Lac, Eric Clottes.   

Abstract

Clenbuterol, a beta2-adrenergic-receptor agonist, is known to provoke muscle hypertrophy and a slow-to-fast phenotype change. A more glycolytic phenotype should be paralleled by changes in muscle glycolytic metabolism. Two groups (n=16 for each) of 3-month-old male Wistar rats (UCL: untrained clenbuterol, and ECL: exercised clenbuterol) received a chronic administration of clenbuterol (2 mg/kg body weight/day). Two other groups of animals (U: untrained and E: exercised), were given a 0.9% NaCl solution instead of clenbuterol. E and ECL animals followed an 8-week progressive isometric force strength-training program. Both clenbuterol administration and training resulted in an increase in extensor digitorum longus (EDL) mass despite the fact that this muscle was indirectly mobilised during isometric force strength training. Clenbuterol and training induced a consistent slow-to-fast phenotype change without drastically increasing specific activities of glycolytic enzymes. Except for GAPDH and hexokinase, modifications in glycolytic-enzyme-specific activities were not explained by transcriptional changes. Lactate dehydrogenase activity was not affected by clenbuterol but was strongly augmented by training. In EDL of ECL rats, both treatments presented an opposite effect compensating each other. GLUT1 mRNA expression was augmented in EDL of UCL and ECL animals, whereas monocarboxylate transporter 1 mRNA amounts were decreased in EDL of UCL rats. Citrate synthase activity was reduced by clenbuterol treatment but remained unchanged in EDL of E animals. Creatine kinase activity was enhanced only by clenbuterol alone. These data show that clenbuterol-induced muscle hypertrophy and slow-to-fast phenotype changes are not associated with a glycolytic-enzyme-activity increase. They also suggest that in EDL isometric force strength training can reverse clenbuterol-induced molecular adaptations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093970     DOI: 10.1007/s00424-006-0122-1

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  40 in total

1.  Effects of beta 2-agonist administration and exercise on contractile activation of skeletal muscle fibers.

Authors:  G S Lynch; A Hayes; S P Campbell; D A Williams
Journal:  J Appl Physiol (1985)       Date:  1996-10

Review 2.  Drugs and sport. Research findings and limitations.

Authors:  P M Clarkson; H S Thompson
Journal:  Sports Med       Date:  1997-12       Impact factor: 11.136

3.  Decreased monocarboxylate transporter 1 in rat soleus and EDL muscles exposed to clenbuterol.

Authors:  T Kitaura; N Tsunekawa; H Hatta
Journal:  J Appl Physiol (1985)       Date:  2001-07

4.  Stimulation of muscle growth by clenbuterol: lack of effect on muscle protein biosynthesis.

Authors:  P J Reeds; S M Hay; P M Dorwood; R M Palmer
Journal:  Br J Nutr       Date:  1986-07       Impact factor: 3.718

5.  The biochemical effects of clenbuterol: with particular reference to taurine and muscle damage.

Authors:  C J Waterfield; M Jairath; D S Asker; J A Timbrell
Journal:  Eur J Pharmacol       Date:  1995-07-01       Impact factor: 4.432

6.  Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity.

Authors:  T S Tsao; J Li; K S Chang; A E Stenbit; D Galuska; J E Anderson; J R Zierath; R J McCarter; M J Charron
Journal:  FASEB J       Date:  2001-04       Impact factor: 5.191

7.  A trial of clenbuterol in bronchial asthma.

Authors:  G Anderson; E Wilkins
Journal:  Thorax       Date:  1977-12       Impact factor: 9.139

8.  Modification of body composition by clenbuterol in normal and dystrophic (mdx) mice.

Authors:  N J Rothwell; M J Stock
Journal:  Biosci Rep       Date:  1985-09       Impact factor: 3.840

9.  Effects of muscle activity and fiber composition on glucose transport and GLUT-4.

Authors:  L A Megeney; P D Neufer; G L Dohm; M H Tan; C A Blewett; G C Elder; A Bonen
Journal:  Am J Physiol       Date:  1993-04

10.  Enolase activity and isoenzyme distribution in human brain regions and tumors.

Authors:  J Joseph; F F Cruz-Sánchez; J Carreras
Journal:  J Neurochem       Date:  1996-06       Impact factor: 5.372

View more
  13 in total

1.  Acute supra-therapeutic oral terbutaline administration has no ergogenic effect in non-asthmatic athletes.

Authors:  Anthony M J Sanchez; Fabio Borrani; Marie Amélie Le Fur; Anais Le Mieux; Virgile Lecoultre; Guillaume Py; Christophe Gernigon; Katia Collomp; Robin Candau
Journal:  Eur J Appl Physiol       Date:  2012-07-06       Impact factor: 3.078

Review 2.  Humanized animal exercise model for clinical implication.

Authors:  Dae Yun Seo; Sung Ryul Lee; Nari Kim; Kyung Soo Ko; Byoung Doo Rhee; Jin Han
Journal:  Pflugers Arch       Date:  2014-03-21       Impact factor: 3.657

3.  Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease.

Authors:  Songtao Li; Baodong Sun; Mats I Nilsson; Andrew Bird; Mark A Tarnopolsky; Beth L Thurberg; Deeksha Bali; Dwight D Koeberl
Journal:  FASEB J       Date:  2012-09-19       Impact factor: 5.191

4.  β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease.

Authors:  Dwight D Koeberl; Songtao Li; Jian Dai; Beth L Thurberg; Deeksha Bali; Priya S Kishnani
Journal:  Mol Genet Metab       Date:  2011-11-11       Impact factor: 4.797

5.  Chronic clenbuterol treatment compromises force production without directly altering skeletal muscle contractile machinery.

Authors:  G Py; C Ramonatxo; P Sirvent; A M J Sanchez; A G Philippe; A Douillard; O Galbès; C Lionne; A Bonnieu; A Chopard; O Cazorla; A Lacampagne; R B Candau
Journal:  J Physiol       Date:  2015-02-27       Impact factor: 5.182

6.  Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle.

Authors:  Dwight D Koeberl; Xiaoyan Luo; Baodong Sun; Alison McVie-Wylie; Jian Dai; Songtao Li; Suhrad G Banugaria; Y-T Chen; Deeksha S Bali
Journal:  Mol Genet Metab       Date:  2011-02-13       Impact factor: 4.797

7.  β-Adrenergic stimulation does not activate p38 MAP kinase or induce PGC-1α in skeletal muscle.

Authors:  Sang Hyun Kim; Meiko Asaka; Kazuhiko Higashida; Yumiko Takahashi; John O Holloszy; Dong-Ho Han
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-02-26       Impact factor: 4.310

8.  Chronic β2 -adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men.

Authors:  Morten Hostrup; Johan Onslev; Glenn A Jacobson; Richard Wilson; Jens Bangsbo
Journal:  J Physiol       Date:  2017-11-12       Impact factor: 5.182

Review 9.  Muscle plasticity and β₂-adrenergic receptors: adaptive responses of β₂-adrenergic receptor expression to muscle hypertrophy and atrophy.

Authors:  Shogo Sato; Ken Shirato; Kaoru Tachiyashiki; Kazuhiko Imaizumi
Journal:  J Biomed Biotechnol       Date:  2011-11-15

10.  CL316,243, a β3-adrenergic receptor agonist, induces muscle hypertrophy and increased strength.

Authors:  Daniela Puzzo; Roberto Raiteri; Clotilde Castaldo; Raffaele Capasso; Ester Pagano; Mariateresa Tedesco; Walter Gulisano; Lisaveta Drozd; Pellegrino Lippiello; Agostino Palmeri; Pietro Scotto; Maria Concetta Miniaci
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.